Patient P-01801
Therapy response
Declining
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 39 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 46 SC-12 recommended — Supportive Compound SC-12
- Day 47 Patient accepted — Started SC-12 in the companion
- Day 53 GI symptom burden −17% vs expected — Supportive Compound SC-12
- Day 59 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 39.
Primary contributors, last 14 days
- GI instability+21
- Nutritional resilience-16
- Inflammatory activity+11
- Toxicity-8
- Treatment adherence-3
What helped?
- Supportive Compound SC-12Day 46Result: symptom burden −17%
LIFE OS recommendation
GI Support Protocol GI-04
91%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 39/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 73 and rising
- WearableSleep 5.1 h, below personal baseline
- Autonomic recovery ↓45
- WearableResting HR 76 bpm
- WearableShort sleep window
- Inflammatory signalling ↑25
- BloodInflammatory load index 66
- Drug metabolism and exposure ↑20
- BloodToxicity index 41
DNA
Fictional pharmacogenomic panel
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.2 · butyrate capacity 39/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 52 ms
- Sleep
- 5.3 h
- Steps
- 6,859
- Resting HR
- 75 bpm
Daily log: GI score 73, nutritional resilience 31, adherence 39.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01531 | 51% | S14 | ME-01 | improved | 51 |
| P-01447 | 46% | S15 | GI-04 | improved | 44 |
| P-01615 | 45% | S14 | ME-01 | improved | 48 |
| P-01720 | 45% | S14 | NP-02 | improved | 47 |
| P-01412 | 44% | S14 | NP-02 | improved | 49 |
| P-01656 | 44% | S14 | ME-01 | improved | 41 |
| P-01675 | 44% | S14 | NP-02 | improved | 38 |
| P-01728 | 44% | S14 | SC-12 | improved | 41 |
| P-01736 | 44% | S03 | ME-01 | improved | 46 |
| P-01887 | 44% | S12 | ME-01 | improved | 43 |
| P-01368 | 43% | S14 | GI-04 | improved | 53 |
| P-01834 | 43% | S14 | NP-02 | improved | 44 |